BioMarin Pharmaceutical BMRN
Nasdaq · Pharmaceutical Preparations · $11.3BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $1.8B | $2.1B | $2.4B | $2.9B | $3.2B | +12.9% | +14.9% | |
| Cost of Revenue (COGS) | $470.5M | $503.0M | $532.1M | $580.2M | $717.4M | +23.6% | +11.1% | |
| Research & Development (R&D) | $628.8M | $649.6M | $746.8M | $747.2M | $921.9M | +23.4% | +10.0% | |
| Selling, General & Admin (SG&A) | $759.4M | $823.2M | $892.4M | $1.0B | $1.2B | +14.3% | +11.0% | |
| Operating Income (EBIT) | $-82.3M | $161.0M | $185.8M | $484.2M | $409.5M | −15.4% | — | |
| Interest Expense | $15.3M | $16.0M | $17.3M | $12.7M | $10.9M | −14.0% | −8.2% | |
| Income Tax Expense | $-11.3M | $8.0M | $20.9M | $114.9M | $133.6M | +16.3% | — | |
| GAAP Net Income | $-64.1M | $141.6M | $167.6M | $426.9M | $348.9M | −18.3% | — | |
| Diluted EPS | $-0.35 | $0.75 | $0.87 | $2.21 | $1.80 | −18.6% | — | |
| Diluted Shares | 182.9M | 189.0M | 191.6M | 196.7M | 197.4M | +0.3% | +1.9% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $587.3M | $724.5M | $755.1M | $942.8M | $1.3B | +39.1% | +22.2% | |
| Inventory | $776.7M | $894.1M | $1.1B | $1.2B | $1.3B | +5.4% | +13.7% | |
| Total Current Assets | $2.3B | $2.8B | $3.0B | $3.2B | $4.0B | +22.3% | +14.8% | |
| Total Assets | $6.0B | $6.4B | $6.8B | $7.0B | $7.6B | +8.7% | +6.0% | |
| Total Current Liabilities | $546.5M | $588.9M | $1.2B | $607.0M | $759.0M | +25.0% | +8.6% | |
| Total Debt (Short + Long Term) | $4.8B | $4.8B | $4.8B | $4.8B | $597.2M | −87.6% | −40.7% | |
| Total Liabilities | $1.7B | $1.8B | $1.9B | $1.3B | $1.5B | +13.2% | −3.5% | |
| Stockholders' Equity | $4.3B | $4.6B | $5.0B | $5.7B | $6.1B | +7.6% | +9.3% | |
| Net Cash / (Net Debt) | $-4.2B | $-4.1B | $-4.1B | $-3.9B | $714.5M | +118.4% | — | |
| Invested Capital | $8.5B | $8.7B | $9.0B | $9.5B | $5.4B | −43.7% | −10.9% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $304.5M | $175.9M | $159.3M | $572.8M | $828.0M | +44.5% | +28.4% | |
| Depreciation & Amortization (D&A) | $108.0M | $102.0M | $104.4M | $96.4M | $79.6M | −17.5% | −7.4% | |
| Stock-Based Compensation (SBC) | $197.3M | $196.3M | $207.1M | $201.6M | $181.4M | −10.0% | −2.1% | |
| Capital Expenditures (CapEx) | $95.6M | $121.0M | $96.7M | $85.4M | $103.0M | +20.6% | +1.9% | |
| Free Cash Flow (FCF) | $209.0M | $54.9M | $62.6M | $487.4M | $725.0M | +48.7% | +36.5% | |
| True FCF (ex-SBC Owner Cash) | $11.7M | $-141.4M | $-144.5M | $285.8M | $543.5M | +90.2% | +161.1% | |
| Share Repurchases (Buybacks) | $0 | $0 | — | — | $0 | — | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.